[Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis].
S Iu
SIu
Milovanova
T N
TN
Lopatkina
L V
LV
Kozlovskaia
T N
TN
Krasnova
D016263:AIDS-Associated Nephropathy / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000187:drug effects; D001402:B-Lymphocytes / Q000276:immunology; D003449:Cryoglobulinemia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab